Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma

Cancer Letters

Volumn 199, Issue 2, 2003, Pages 131-138

  Koda, Masaharu ^a   Yashima, Kazuo ^a   Kawaguchi, Koichirou ^a   Andachi, Hironobu ^a   Hosoda, Akihide ^a   Shiota, Goshi ^b   Ito, Hisao ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Fhit; Gallbladder carcinoma; Immunohistochemistry; Mlh1; P53

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN MLH1; PROTEIN P53;

ADENOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GALLBLADDER CARCINOMA; GALLBLADDER TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 0142028064     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00385-9     Document Type: Article

References (42)

1. Lazcano-Ponce E., Miquel J.F., Ferrecio C., Wistuba I.I., Munoz N., Alonso de Ruiz P., Urista G., Herrero R., Nervi F. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J. Clin. 51:2001;349-364.
2. Tazuma S., Kajiyama G. Carcinogenesis of malignant lesions of the gallbladder: the impact of chronic inflammation and gallstones. Langenbecks Arch. Surg. 386:2001;224-229.
3. Kozuka S., Tubone N., Ysaui A., Hachisuka K. Relation of adenoma to carcinoma in the gallbladder. Cancer. 50:1982;2226-2234.
4. Kijima H., Watanabe H., Iwafuchi M., Ishihara N. Histogenesis of gallbladder carcinoma from investigate of early carcinoma and microcarcinoma. Acta Pathol. Jpn. 39:1989;235-244.
5. Kim Y.T., Kim J., Jang Y.H., Lee W.J., Ryu J.K., Park Y.K., Kim S.W., Kim W.H., Yoon Y.B., Kim C.Y. Genetic alteration in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett. 169:2001;59-68.
6. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., Macue P., Druck T., Croce C.M., Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma- associated t (3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 84:1996;587-597.
7. Croce C.M., Sozzi G., Huebner K. Role of FHIT in human cancer. J. Clin. Oncol. 17:1999;1618-1624.
8. Kitamura A., Yashima K., Okamoto E., Andachi H., Hosoda A., Kishimoto Y., Shiota G., Ito H., Kaibara N., Kawasaki H. Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology. 61:2001;205-211.
9. Tanaka H., Shimada Y., Harada H., Shindou M., Hatooka S., Imamura M., Ishizaki K. Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res. 58:1998;3429-3434.
10. Zochbauer-Muller S., Fong K.M., Maitra A., Lam S., Geradts J., Ashfaq R., Virmani A.K., Milchgrub S., Gazdar A.F., Minna J.D. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 61:2001;3581-3585.
11. Wistuba I.I., Ashfaq R., Maitra A., Alvarez H., Riquelme E., Gazdar A.F. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am. J. Pathol. 160:2002;2073-2079.
12. Eshleman J.R., Makowitz S.D. Mismatch repair defects in human carcinogenesis. Hum. Mol. Genet. 5:1996;1489-1494.
13. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170.
14. Peltomaki P., Vasen H.F. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and result of a collaborative study. The international collaborative group on hereditary nonpolyposis colorectal cancer. Gastroenterology. 113:1997;1146-1158.
15. Halling K.C., Harper J., Moskaluk C.A., Thibodeau S.N., Petroni G.R., Yustein A.S., Tosi P., Minacci C., Roviello F., Piva P., Hamilton S.R., Jackson C.E., Powell S.M. Origin of microsatellite instability in gastric cancer. Am. J. Pathol. 155:1999;205-211.
16. Ward R., Meagher A., Tomlinson I., O'Connor T., Norrie M., Wu R., Hawkins N. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut. 48:2001;821-829.
17. Chiaravalli A.M., Furlan D., Facco C., Tibiletti M.G., Dionigi A., Casati B., Albarello L., Riva C., Capella C. Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch. 438:2001;39-48.
18. Herman J.G., Umar A., Polyak K., Graft J.R., Ahuja N., Issa J.P.J., Markowitz S., Wilson J.K.V., Hamilton S.R., Kinzler K.W., Kane M.F., Kolodner R.D., Vogelstein B., Kunkel T.A., Baylin S.B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA. 95:1998;6870-6875.
19. Thibodeau S.N., French A.J., Roche P.C., Cunningham J.M., Tester D.J., Lindor N.M., Moslein G., Baker S.M., Liskay R.M., Burgart L.J., Honchel R., Halling K.C. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair gene. Cancer Res. 56:1996;4836-4840.
20. Marcus V.A., Madlensky L., Gryfe R., Kim H., So K., Millar A., Temple L.K., Hsieh E., Hiruki T., Narod S., Bapat B.V., Gallinger S., Redston M. Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am. J. Surg. Pathol. 23:1999;1248-1255.
21. Fong L.Y.Y., Fidanza V., Zanesi N., Lock L.F., Siracusa L.D., Mancini R., Siprashvili Z., Ottey M., Martin S.E., Druck T., McCue P.A., Croce C.M., Huebner K. Muir-Torre-like syndrome in Fhit-deficient mice. Proc. Natl. Acad. Sci. USA. 97:2001;4742-4747.
22. Mori M., Mimori K., Masuda T., Yoshinaga K., Yamashita K., Matsuyama A., Inoue H. Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit expression in colorectal carcinoma. Cancer Res. 6:2001;7379-7382.
23. Andachi H., Yashima K., Koda M., Kawaguchi K., Kitamura A., Hosoda A., Kishimoto Y., Shiota G., Ito H., Makino M., Kaibara N., Kawasaki H., Murawaki Y. Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma. Br. J. Cancer. 87:2002;441-445.
24. General Rules for Surgical and Pathological Studies on Cancer of the Biliary Tract. fourth ed :1997;Kanehara, Tokyo. (in Japanese).
25. Hermanek P., Sobin L.H. UICC TNM Classification of Malignant Tumors. fourth ed :1987;Springer, New York.
26. Hao X.P., Willis J.E., Pretlow T.G., Rao J.S., MacLnnan G.T., Talbot I.C., Pretlow T.P. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res. 60:2000;18-21.
27. Beak M.J., Kang H., Kim S.E., Park J.H., Lee S.J., Paik Y.K., Kim H. Expression of hMLH1 is inactivated in the gastric adenomas with enhanced microsatellite instability. Br. J. Cancer. 85:2001;1147-1152.
28. Sozzi G., Pastorino U., Moiraghi L., Tagliabue E., Pezzella F., Ghirelli C., Tornielli S., Sard L., Huebner K., Pierotti M.A., Croce C.M., Pilotti S. Loss of Fhit function in lung cancer and preinvasive bronchial lesions. Cancer Res. 58:1998;5032-5037.
29. Mori M., Mimori K., Shiraishi T., Alder H., Inoue H., Tanaka Y., Sugimachi K., Huebner K., Croce C.M. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res. 60:2000;1177-1182.
30. Boland C.R., Thibodeau S.N., Hamilton S.R., Sindransky D., Eshleman J.R., Burt R.W., Melzer S.J., Rodriguez-Bigas M.A., Fodde R., Ranzani G.N., Srivastava S. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58:1998;5248-5257.
31. Kruse R., Rutten A., Lamberti C., Hosseiny-Malayeri H.R., Wang Y., Ruelfs C., Jungck M., Mathiak M., Ruzicka T., Hartschuh W., Bisceglia M., Friedl W., Propping P. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am. J. Hum. Genet. 63:1998;63-70.
32. Hilgers W., Kern S.E. Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer. 26:1999;1-12.
33. Hilgers W., Koerkamp B.G., Geradts J., Tang D.J., Yeo C.J., Hruban R.H., Kern S.E. Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas. Genes Chromosomes Cancer. 27:2000;239-243.
34. Kim Y.W., Huh S.H., Park Y.-K., Yoon T.Y., Lee S.M., Hong S.H. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol. Rep. 8:2001;1127-1132.
35. Watanabe H., Date K., Itoi T., Matsubayashi H., Yokoyama N., Yamano M., Ajioka Y., Nishikura K. Histological and genetic changes in malignant transformation of gallbladder adenoma. Ann. Oncol. 10:1999;136-139.
36. Takei K., Watanabe H., Itoi T., Saito T. p53 and Ki-67 immunoreactivity and nuclear morphometry of 'carcinoma-in-adenoma' and adenoma of the gall-bladder. Pathol. Int. 46:1996;908-917.
37. Marchetti A., Pellegrini S., Sozzi G., Bertacca G., Gaeta P., Buttitta F., Carnicelli V., Griseri P., Chella A., Angeletti C.A., Pierotti M., Bevilacqua G. Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. Br. J. Cancer. 78:1998;73-78.
38. Wistuba I.I., Sugio K., Hung J., Kishimoto Y., Virmani A.K., Roa I., Albores-Saavedra J., Gazdar A.F. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res. 55:1995;2511-2515.
39. Wistuba I.I., Miquel J.F., Gazdar A.F., Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum. Pathol. 55:1995;2511-2515.
40. Roa I., Araya J.C., Villaseca M., Aretxabala X.D., Riedemann P., Endoh K., Roa J. Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression. Gastroenterology. 111:1996;232-236.
41. Wee A., Teh M., Raju G.C. Clinical importance of p53 protein in gallbladder carcinoma and its precursor lesion. J. Clin. Pathol. 47:1994;232-236.
42. Wistuba I.I., Gazdar A.F., Roa I., Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum. Pathol. 27:1996;360-365.